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ABSTRACT  
In 2018, the EU Court of Justice ruled that gene edited organisms “are GMOs and are, in 
principle, subject to the obligations laid down by the GMO directive [EU Directive 
2001/18/EC]”. While the EU Court of Justice has established an equivalence between gene 
edited organisms and GMOs, how have national institutions and committees from EU 
member states positioned themselves regarding the use of gene editing in agriculture? In 
order to answer this question, this article examines and compares 11 official reports and 
position statements from 7 European countries: Germany, France, the Netherlands, Italy, 
Spain, Denmark, and Sweden. The various kinds of issues that are addressed and arguments 
that are made in the reports are coded into large categories (innovation, risk, ethics, 
legislation, etc.) and are analysed. The paper discusses the main similarities and differences 
in terms of how the governance of gene editing is problematized. For instance, while some 
reports consider gene editing in terms of technology, risk and regulation, others situate 
gene editing within larger debates about agriculture, intellectual property, ethics, public 
participation, and the responsibility of scientists. The paper aims to provide a useful resource 
to broaden debates on the future regulation of gene editing within and beyond Europe. It 
also calls for an analysis of the objectification of gene editing: how are gene edited 
organisms rendered tangible, discussable and public via policy processes? How are they tied 
to national territories, identities, histories or products and how does this (re)nationalizing of 
gene edited organisms matter within and beyond EU member states?  
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Recent responses from policy makers concerning the regulation of gene editing in the field 
of agriculture have shown remarkable divergences. Consider, on the one hand, the position 
of the US Department of Agriculture (2018): crops modified via gene editing “do not require 
regulatory oversight.” The US Department of Agriculture considers gene edited crops as 
innovative, safe, and healthy. Consider, on the other hand, the ruling of the EU Court of 
Justice (2018): gene edited organisms “are GMOs and are, in principle, subject to the 
obligations laid down by the GMO directive [EU Directive 2001/18/EC]”. While establishing 
an equivalence between gene edited organisms and GMOs, the EU Court of Justice argues 
that gene edited organisms can potentially be risky, and stresses the need to respect the 
precautionary principle.  
While the position at the EU level is clear-cut, what about positionings within individual 
European member states? How have national institutions and committees positioned 
themselves regarding the use of gene editing in agriculture? Do they have similar views on 
the issue or are there significant differences?  
In order to answer these questions this article examines official reports and position 
statements from seven European countries: Germany, France, the Netherlands, Italy, Spain, 
Denmark, and Sweden. We have decided to focus on these seven countries for they are the 
only European countries in which at least one official statement regarding the use and 
regulation of gene editing in agriculture has been published.1  
 
Today the most prominent gene editing technique is CRISPR/Cas9. CRISPR (for Clustered 
regularly interspaced short palindromic repeats) sequences have first been described in 1987 
and in the 2000s their capacity to “edit” genes has been recognized. The CRISPR/Cas9 
technology - often called “gene scissors” - makes it possible to change genetic sequences 
easier, quicker and cheaper than traditional biotechnology methods and has thus been 
celebrated as “the iPhone of biotechnology” (Galanopoulo 2016) and the greatest advance 
in biotechnology since the PCR machine.  
2015 is the year that CRISPR/Cas9 made it to the headlines of many academic journals as 
well as media outlets. The publication in April 2015 of an article on the modification of 
human embryos in the journal Protein & Cell (Liang et al. 2015) raised international concern 
                                                   
1 We have searched for reports and statements from all 28 EU member states, with the exception of the UK as its 
future membership of the EU is uncertain. According to our search, in only 7 countries reports on gene editing 
have been published. This does not mean, however, that other EU member states have not reflected upon the 
issue: Eriksson (2018) has provided a detailed list with statements and opinions by EU actors that, beyond the 
countries we identified, also includes Finland; and Svingen (2019) has analyzed the positions of the Norwegian 
Biotechnology Advisory Board. 
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and calls for a moratorium were published in journals such as Nature (Lanphier et al. 2015) 
and Science (Baltimore et al. 2015). From 2015 onwards, CRISPR/Cas9 became the object of 
wide and rich debates. Concerns have been raised about ethical issues, about economic 
issues related to patenting, about environmental and health risks, and about the possibility 
to produce new kinds of weapons. The issues raised resemble the types of issues that can be 
observed in debates around GMOs and synthetic biology, which generally revolve around 
ELSI issues, that is the ethical, legal, and social implications of science (Baumann 2016).  
At the end of 2015, the first international summit on human gene editing was held in 
Washington (Jasanoff et al. 2015). After this summit, numerous countries have issued reports 
or statements about human gene editing, including the UK, the US, Germany, France, the 
Netherlands, India, Denmark, Canada, and Australia. Various other conferences such as 
CRISPRcon have been organised (since 2017) in order to address scientific, ethical, legal and 
policy issues. Gene editing then broke again the headlines in November 2018 when scientist 
He Jiankui announced that he had modified the embryos of twins via gene editing; an 
announcement made just a few days before the second international summit on human 
genome editing in Hong Kong (Meyer 2018). As in 2015, the organizing committee released 
a statement about the use of gene editing in human embryos and many countries and 
scientific institutions issued position statements thereafter. 
While human gene editing has been much discussed and written about, much less has been 
written on the use of gene editing in agriculture and its implications in terms of governance, 
regulation, economics, social and ethical issues. There have been, on the one hand, several 
reports on the topic - for example the report New Techniques in Agricultural Biotechnology 
published by the European Commission in 2017 - as well as international conferences on the 
topic, such as Genome Editing: Applications in Agriculture - Implications for Health, 
Environment and Regulation held at the OECD in 2018. On the other hand, only a few 
academic articles have discussed and examined the wider implications of gene editing. 
Gutzmann et al. (2017) discuss the need for interdisciplinarity and public engagement when 
reflecting upon the ethics and governance of CRISPR-based gene drives in agriculture. They 
conclude: “Scientists, social scientists, regulators, advocacy groups, and public audiences 
have been and must continue to engage clearly and candidly with one another to shape the 
future of this technology”. Helliwell et al. (2019) analyse how non-governmental 
organisations contest and challenge the wider politics, framings, and power issues in the 
debate. Holman (2019) has compared regulatory frameworks, in particular between the US, 
who are moving towards less regulation, and the EU, who intents to regulate gene editing 
via the “same burdensome regime” than for GMOs. A wide scope is provided by Erikkson et 
al. (2019), who look into regulations in Argentina, Brazil, Chile, Colombia, Canada, the United 
States and Australia in comparison to the EU approach. They also discuss some of the 
concerns raised in the aftermath of the ruling of the EU Court of Justice: concerns with trade 
disruptions, agricultural innovation, and the difficulty to detect and label gene edited 
products. The present article aims to contribute to this recent and emerging academic 
literature on the social, ethical, legal and political aspects of the use of gene editing in 
agriculture. Its originality consists in examining and comparing how different councils, 
commissions and/or institutions within the EU have addressed gene editing. Such an 
approach is useful, we hope, because governance and public debates on gene editing occur 
both on national and transnational levels and since comparisons can reveal the specificities 
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of a given position, and point to commonalities and potential divergences between 
countries and institutions. 
 
We have selected and analysed altogether 11 texts published in 7 countries (see table 1). 
The reports have all been published from 2015 onwards, which doesn’t come as a surprise 
since gene editing rose to prominence in 2015 both within and beyond academic circles. 
There is a notable heterogeneity regarding the institutions that have published them: 
independent councils (i.e. the French Haut Conseil des Biotechnologies, the Danish Council 
on Ethics); ministerial commissions (i.e. the Spanish Comisión Nacional de Bioseguridad) and 
intra-ministerial commissions (i.e. the Italian Comitato Nazionale per la Biosicurezza, le 
Biotecnologie e le Scienze della Vita); as well as scientific institutions (i.e. the common ethics 
committee of INRA, CIRAD, and IFREMER, the Max Planck Society). While the provenances 
and forms of these texts are heterogeneous, they were all written in response to regulatory 
concerns associated with the future governance of - and debates on - gene editing and all 
include recommendations.  
In order to examine the content of these texts in more detail, we have used what social 
scientists call a “grounded method”: we have scrutinized the texts to seek for the various 
kinds of issues that are addressed and arguments that are mobilised, and we then coded 
these into eight large groups (innovation, risk, ethics, etc.). To these eight categories we 
added a ninth rubric: the reports’ recommendations (see table 2). 
In a second round of analysis, we have examined if and how, in each of these 11 reports, the 
eight themes have been addressed and what kinds of recommendations they draw. Table 2 
provides a summary of the results of our analysis.  
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Table 1: Reports and position statements on gene editing according to their country of origin,  
the institution(s) that published them, the title and year of publication 
 
Country Institution(s) Title Year; number of pages 
Germany  Nationale Akademie der Wissenschaften 
Leopoldina, Deutsche Forschungsgemeinschaft, 
Deutsche Akademie der Technikwissenschaften, 
Union der deutschen Akademien der 
Wissenschaften 
The opportunities and limits of genome 
editing 
2015; 16 pages 
Germany  Max Planck Gesellschaft Statement on the scientific and translational 
impact of genome editing and arising 
ethical, legal and societal issues  
2019; 4 pages and discussion 
paper of 29 pages  
France Haut Conseil des Biotechnologies (HCB) Avis sur les nouvelles techniques 
d'obtention de plantes (New Plant Breeding 
Techniques - NPBT) 
2017; 1 report of 60 pages + 12 
pages of appendix and 1 report of 
69 pages + 21 pages of appendix   
France Comité consultatif commun d’éthique INRA-
CIRAD-IFREMER 
Avis 11 sur les nouvelles techniques 
d’amélioration génétique des plantes 
2018; 36 pages 
Denmark The Danish Council on Ethics Statement on GMO and ethics in a new era  2019; 28 pages 
Italy Società Italiana di Genetica Agraria, Società ̀
Italiana di Biologia Vegetale (SIGA/SIBV) 
Position document on genome editing 
techniques applied to agriculture 
2016; 13 pages 
Italy  Comitato Nazionale per la Biosicurezza, le 
Biotecnologie e le Scienze della Vita (CNBBSV) 
Le New Breeding Techniques (NBT): 1 - La 
posizione dei principali portatori di interesse 
Italiani 
2017; 15 pages + 11 pages of 
appendix 
Spain Ministerio de Agricultura y Pesca, Alimentación y 
Medio Ambiente (Comisión Nacional de 
Bioseguridad)  
Comentarios de la Comisión nacional de 
bioseguridad. Sobre las nuevas técnicas de 
mejora vegetal (NTMV) 
2015; 5 pages 
Spain  Ministerio para la Transición Ecológica (Comisión 
Nacional de Bioseguridad)  
Informe de la Comisión Nacional de 
Bioseguridad sobre la mutagénesis dirigida 
(“edición genética”) 
2019; 6 pages 
The Netherlands  Royal Netherlands Academy of Arts and Sciences  Genome Editing - Position Paper of the 
Royal Netherlands Academy of Arts and 
Sciences 
2016; 6 pages 
Sweden Swedish Board of Agriculture Consequences of the EC-ruling according to 
Swedish companies and research groups 
2018; 18 pages 
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 Table 2: Arguments made in official texts  All words are direct quotes unless marked otherwise (italics and brackets) 
 Innovation Risk Legislation Food Quality Economy Epistemology Ethics Intellectual 
property 
Recommendations 
Denmark 
(2019) 
simpler; more 
accurate 
gene modification [is 
not risky] per se; [no] 
greater risk than 
conventional plant 
breeding technologies 
[legislation is] 
paradox[ical] because 
required risk 
assessments are too 
expensive, thus 
favouring research 
carried out by large 
[...]corporations  
develop plants that are 
more resistant to 
disease, that are 
healthier to eat, that 
can keep for longer 
problematic if 
development and 
marketing is 
obstructed; [only] 
multinational seed 
companies can afford 
risk assessing their 
GMOs 
new genome editing 
techniques give rise to 
new research, 
however, new research 
is crucially inhibited by 
current EU legislation 
morally, we ought to 
use the types of GMOs 
that could be 
beneficial;  
genetic modification is 
wrong because it is 
unnatural 
[Patents on GMO 
varieties] led to 
widespread criticism; 
farmers [...] are 
forced to buy the 
seeds from the seed 
company 
not put obstacles in 
the way of GMOs 
based on the 
technology used to 
produce them 
France (2017) efficiency; rapid   different kinds of risks 
assessed; uncertainty; 
the main risk would be 
related to the presence 
[...] of the effectors  
different 
interpretations of EU 
directive possible; 
legal uncertainty; grey 
zone 
nutritional quality can 
be cited   
the nature of the 
products put on the 
market, the 
perceptions and 
reactions of consumers 
and actors in the 
sectors are difficult to 
anticipate to date 
in terms of research 
needs, [there is a] 
need to reduce some 
of the existing 
uncertainties about 
NPBTs 
discussed at length research on 
intellectual property 
in the field of plant 
biotechnology may 
be necessary 
framework [...] based 
on both the 
precautionary 
principle and a 
principle of 
proportionality; in-
depth juridical study 
should be done; case 
by case  
France (2018) precious tool; 
possibilities; limits; 
perceived as more 
precise, more rapid, 
easier, [...] and less 
expensive  
environmental, 
sanitary, agricultural, 
economic, social and 
political [risks need 
consideration]; 
uncertainties 
be active in 
discussions [...] on 
regulatory questions;  
two types of  
regulatory systems 
envisaged; legal 
uncertainty  
improve [...] 
nutriments 
render explicit 
contradiction between 
[...] competition and 
[...] the agroecological 
transition  
interdisciplinary; 
transdisciplinary; 
common good; public 
research; co-
construction [need 
consideration]; 
pertinent tool for 
knowing life/genes 
defence of the ethical 
values associated to 
the COV system [which 
guarantees just 
intellectual 
recognition and 
availability of genetic 
resources]  
be active in 
discussions [...] on 
intellectual property; 
patentability of 
CRISPR-Cas9 system 
[...] is not subject to 
litigation; benefits of 
open source 
10 recommendations  
Germany 
(2015) 
simple; time-saving; 
cost-effective; more 
efficient; more 
controllable 
risk is primarily 
associated with gene 
drive technologies 
 
legally acceptable in 
many areas; 
regulatory 
consequences for the 
classification, 
assessment and 
approval of the plant 
varieties obtained by 
new molecular 
breeding methods 
[should be taken] 
indistinguishability 
between GEOs and 
animals or plants bred 
by natural processes 
require new processes 
for the product-based 
assessment and 
regulation of GMOs 
 
only indirectly 
mentioned in 
statements about the 
potentials of possible 
applications 
 
[detailed discussion 
regarding] new 
dimensions for all 
molecular biological 
basic research and for 
potential applications 
in plant breeding, 
industrial 
biotechnology and 
biomedicine 
 
ethically […] 
acceptable in many 
areas  
/ applications and 
ethical or legal 
problems should not 
be mixed up or 
condemned; there 
should be public 
debate on the 
scientific, ethical and 
legal possibilities of 
genome editing and 
on its limits 
Germany 
(2019) 
much simpler; 
versatile platform for 
precise alterations  
research drawing on 
new gene editing 
techniques should be 
carried out, in order to 
understand the risks 
Directive 2001/18 
requires revision and 
updating 
interest to the 
consumer, such as 
reduced gluten 
content 
/ enormous potential 
both for 
understanding 
biological principles 
and for improving 
human, animal and 
plant health 
it is necessary to 
develop universal 
ethical [...] standards 
with regard to gene 
drives 
ensure license 
practices coherent 
with freedom of 
research and equal 
access to resulting 
applications 
 
pursue new and 
amended legislation  
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…/… Innovation Risk Legislation Food Quality Economy Epistemology Ethics Intellectual 
property 
Recommendations 
Italy (2016) promising; precise; 
predetermined; 
innovation; 
successfully 
predictable risk; 
avoids the risk 
regulatory limbo; 
[regulate as GMOs is 
a] serious mistake  
nutritious; safe compete globally; 
inexpensive food 
/ / / should be excluded 
from Directive 
2001/18/EC 
Italy (2017) innovative; promising; 
precise; excellent 
instrument; low cost 
minor risk; similar 
risks [as conventional 
technologies] 
legislative void; 
uncertain about their 
regulation; outdated 
/ competitiveness; 
import; strategic 
sectors  
/ / important question 
of patentability  
legislation should be 
product oriented; 
revise directive 
Netherlands 
(2016) 
cheaper, more 
efficient, more precise  
need to be vigilant 
and to address social 
and ethical dilemmas 
EU must clarify and, 
where required, 
amend legislation  
higher yields, and 
disease- and pest-
resistance 
negative 
consequences [...] for 
commercial 
applications in 
agriculture and 
horticulture 
significant advances in 
our knowledge 
genome editing […] 
gives rise to critical 
ethical questions 
/ simplification of the 
regulations 
Spain (2015) rapid; useful security  analysis [is 
needed] 
/ quality of the fruit commercial value / / / case by case 
evaluation; product 
and not the process 
Spain (2019) rapid; precision; 
specific; efficiency 
minimal risk; safety for 
health and the 
environment [needs 
consideration]; 
security  
for a revision of the 
actual norms 
regarding GMOs 
these techniques are 
used [...] to improve 
crop quality  
international 
commerce 
advancement of 
European science 
/ / clarifications are 
needed on some 
implementation 
issues; revise the 
current regulation on 
GMOs  
Sweden 
(2018) 
great potential; 
efficient; rapid; 
precision 
risk of losing 
collaborators, 
companies and 
researchers from 
academic institutions  
legal uncertainties; 
ruling [...] means a 
ban on genome edited 
crops  
plant varieties with 
higher quality; 
increased food safety  
expensive 
authorisation 
procedures; less [...] 
funding for research; 
products [...] will not 
reach the market; loss 
of competitiveness; 
obstruct 
commercialisation   
collaboration [...] will 
decrease; loss of 
competitiveness; 
research projects have 
been changed or 
paused  
/ made investments in 
patent [...] will be 
lost; [dependence] 
on licenses from 
biotechnology 
companies  
/ 
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Some texts take a strong stance in favour of the exclusion of gene editing from current 
regulation making claims about the negative consequences for science and economy should 
the EU regulation (i.e. EU Directive 2001/18/EC) not be renewed. This is the case, for 
instance, in the two reports from Italy. The 2016 SIGA/SIBV report says that it would be a 
“serious mistake” to qualify as GMOs gene edited organisms with mutations that are 
indistinguishable from spontaneous ones, and that the “remake of European GMO history” 
will lead to “a nonsense of logic, a scientific absurdity, a legal mess and an economic 
damage altogether”. The 2017 CNBBSV report, albeit a bit softer in tone, is also clearly in 
favour of not regulating gene editing, arguing that there are only “minor risks”, and that the 
2001 EU directive is “inadequate” and that regulation should be “purely product-oriented” 
(and not process-oriented). In a section devoted to market issues, concerns are raised about 
“grave repercussions on strategic sectors [...] with an inevitable loss of international market”. 
The position of the Swedish Board of Agriculture - an assessment of the (mostly negative) 
consequences of the EU Court of Justice ruling - is also in favour of deregulating gene 
editing. It stresses that for “many researchers, the ruling is perceived as very problematic.” 
According to the report, many things will be “lost” due to the ruling: “Made investments in 
patent, staff, research, product development and knowledge”, “competence”, 
“competitiveness”, “control of plant breeding”. Both the positive assessment of gene 
editing, as well as the negative assessment of the ruling are exemplified by the following 
quote:  
“The ruling will have negative effects on the national economy when it comes to both plant and 
animal production. It is counter-productive to make it more difficult to use a technique with 
high precision and with several benefits compared to “older” techniques. Genome editing is a 
brilliant example of technical development being the most important factor to be able to deal 
with challenges regarding food supply, resource management, climate adaptation and the 
environment.” 
In the same vein, the report of the Danish Council on Ethics holds a position which is largely 
in favour of a renewal of EU regulations while putting a stronger emphasis on the solution of 
current planetary crises. A general bottom-line of the Danish Council on Ethics is that CRISPR 
does not carry more or less risk than traditional gene modification, and that, given this 
“fact”, humanity can no longer “afford” not to use CRISPR. In order to strengthen this 
utilitarian position, the authors repeatedly refer to the potential role that genome editing 
could play “in achieving several of the UN’s Sustainable Development Goals from 2015”. 
Beyond that, the authors accuse the existing EU regulatory framework of being 
“paradoxical” while underlining that:  
[this paradoxicality] “raises the question of whether it is ethically problematic if the legislation 
obstructs the development and marketing of GMOs, e.g. those with positive effects, if they are 
not deemed more risky than similar conventional varieties.”  
Despite this vigorous argumentation in favour of CRISPR, the report closes with somewhat 
fragmented recommendations on how to govern gene editing in the future. In these 
9 
recommendations “some members” (the large majority) of the Danish Council on Ethics 
provide practical suggestions on how to adapt current EU regulation, while “one member” is 
granted the space to express that he “cannot support measures to ease the authorisation 
system for GMOs.” 
 At the other end of the spectrum is the 2018 report by the Comité consultatif commun 
d’éthique INRA-CIRAD-IFREMER. This report is the most critical, reflexive and analytical in 
our corpus of texts. The report argues, for instance, that “it is important not to be blinded by 
short-term benefits but to take the time to evaluate long-term risks” and that an “upstream 
inclusive and collective reflexion” is needed. It situates gene editing within larger debates 
about the models and politics of agriculture; it discusses controversies and contestations; 
and it reflects about issues that are not present in any other report, such as recent 
developments in the field of agroecology as well as matters of public participation, social 
justice, and open source. The ten recommendations of the report can be roughly 
summarized as a call for reflexivity, openness and vigilance (for example: consider the forms 
of agriculture, economy and society in relation to CRISPR/Cas9; foster interdisciplinary 
research; discuss about regulation and intellectual property issues). The report by the Danish 
Council on Ethics is somewhat similar to the INRA-CIRAD-IFREMER report in terms of its 
scope: both reports are interdisciplinary (and their authors include philosophers, ethicists, 
plant scientists, environmental scientists, etc.) and they provide a much more systemic 
analysis than the other reports.  
To put it bluntly, we can identify three kinds of reports in our corpus: 
interdisciplinary/systematic ones (France, Denmark); reports that talk in the name of science 
and offer rather cautions assessments regarding technological advantages (Netherlands, 
Germany, Spain); and those with a strong normative and affirmative view (Italy, Sweden).  
Similarities and differences within themes  
The reports provide a more or less broad view of the use of gene editing in agriculture. They 
focus not only on the technical aspects of gene editing, but also on risks and legislation. 
Some issues are, however, present in only a few reports, such as ethics, intellectual property, 
and what we termed “epistemology” (arguments about the kind, importance and usefulness 
of knowledge produced). Let us look in more detail at how innovation, legislation, 
recommendations and the economy have been addressed in the texts.2:  
− The qualifications of gene editing (the theme “innovation”) show remarkable 
similarity, with terms like “simple”, “rapid”, “efficient”, “precise” being used in most 
reports.3  
 
− The legal implications of gene editing are also treated in a similar fashion: most 
reports argue for the need of a “revision” and/or “updating” of current legislation, 
because there are “uncertainties”. Most reports also recommend that legislation 
                                                   
2 We focus on these four themes for they are the ones to which most space is dedicated in the reports. 
3 The 2018 French report is reflective about these terms, and even critical about the use of military metaphors.  
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should be based on products, and not the processes of genetic modification 
anymore.  
 
− There are notable differences regarding the specific recommendations that are 
given. On the one hand, there are reports that have a moderate view: they 
recommend to “amend” and “clarify” legislation because it is “unclear” (i.e. the 
Netherlands, Germany, France). While these reports argue that legislation needs 
modification and further reflection, they refrain from saying what kinds of 
modifications should be done. On the other hand, there are reports that take a more 
normative stance and argue, for example, that gene edited organisms “should be 
excluded” from legislation (Italy).  
 
− Economic issues are also treated differently in the reports. First, in the German 
statements economic aspects are virtually absent.4 Second, in the reports from Spain 
and the Netherlands, they are mentioned very briefly, usually in a couple of 
sentences. Quite frequently these brief considerations of the economic issues 
underline the importance of using gene editing in order to maintain or improve a 
particular branch of agricultural production that is historically intertwined with the 
national territory. For example, the position of the Royal Netherlands Academy of 
Arts and Sciences is that a renewal of the regulation in the EU is needed in the name 
of horticulture. Third, there are reports, like the Italian, Swedish and French ones, that 
treat economic issues in great depth on several pages. The French INRA-CIRAD-
IFREMER report discusses for instance economic risks and the tensions between the 
industrial paradigm (concerned with performance and control) and the agro-
ecological paradigm (concerned with protection and cooperation), and the HCB 
report reflects upon commercialisation, competitiveness, traceability, and consumer 
choices. In the report by the Swedish Board of Agriculture, the negative 
consequences of the EU Court of Justice ruling on the economy are evaluated and 
potatoes, rapeseed and barley are discussed as examples of crops that are important 
for Swedish agriculture. The 2017 CNBBSV report contains discussions of specific 
sectors in agriculture (rice, grapes, wheat, etc.) and the strategic interest thereof for 
Italy. It is interesting to note here that the examples given are always plants but very 
rarely animals.   
Argumentative patterns in relation to GMOs  
In addition to the themes that we identified and analysed, we observed that GMOs often 
serve as a reference frame to make arguments about gene editing. On the one hand, this 
doesn’t come as a surprise since Directive 2001/18/EC is the key legal reference point and 
since the key question can be summarised as “Should gene edited organisms (GEOs) be 
considered as GMOs or not?”. On the other hand, however, references to GMOs are not 
limited to legal aspects only. In fact, several argumentative patterns in relation to GMOs can 
be noted:  
                                                   
4 In the 2019 German statement terms like economy/economic, market, industry/industrial, commercial do not 
appear. In the discussion paper from 2015, there is some discussion, but rather abstract, and in relation to GMOs. 
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1. GEOs are better and different than GMOs: they are safer, more precise, and 
quicker and cheaper to produce. The argument here is that with regards to the 
history of GMOs there has been a differentiation and revolution.  
2. GEOs are comparable to GMOs: there is no scientific evidence that GMOs pose a 
risk, they can thus be considered as safe. Therefore GEOs are also safe. This 
argument relies on the comparability between GMOs and GEOs and - unlike the 
argument above - upon the historical and technical continuity between them.  
3a. GEOs are not GMOs in terms of legislation. GEOs should not be regulated as 
GMOs. The problem with pace and asynchronicity is put forward here: legislation is 
seen as “out of date” with regards to new knowledge and new techniques.   
3b. GEOs are not GMOs in terms of nature. Since it will not be possible to distinguish 
most GEOs from natural mutations, GEOs should be excluded from any legal 
framework. In other words, GEOs’ indistinguishability from nature should lead to their 
unaccountability in law. 
An illustrative example for this modular use of references to GMOs is provided by the report 
of the Danish Council on Ethics. On the one hand, the authors frequently draw comparisons 
between “20 years of GMO risk assessments” and the “absence of particular risks” of GEOs. 
On the other hand, they repeatedly refer to the technical difference of “CRISPR-induced 
mutations” and “traditional mutagenesis”, in order to argue that GMOs and GEOs should 
not be legislated in the same way. In other words, from the Danish Council on Ethics’ point 
of view it seems possible to separate GEOs as objects of risk/non-risk from GEOs as objects 
of legislation. 
 
Gene edited organisms have become, over the past four years, the topic of a wide array of 
texts: reports, statements, rulings, etc. While some of these texts have been published by 
scientific institutions, others have been published by ministerial commissions and advisory 
councils that are involved in concrete acts of doing politics. It is thus fruitful to ask a wider 
question here: What kind of objects are gene edited organisms and how can we grasp their 
political dimensions? In order to answer this question, let us consider the following quote by 
Vytenis Andriukaitis, the current EU commissioner for Health and Food Safety:  
“new breeding techniques can help us tackle some profound challenges such as food security, 
food intolerances, or climate change. Examples include low-gluten, non-transgenic wheat [...] 
Or potatoes with a non-browning trait and producing less asparagine have been developed 
through gene editing. These potatoes provide the potential for the formation of acrylamide to 
be reduced by 60-70% when potatoes are baked, fried or roasted at high temperatures. (This 
could completely ‘save’ Belgium fries)” (Andriukaitis 2019). 
Gene edited organisms are very specific objects. They bring together not only technological 
and scientific considerations but also issues to do with consumers and health. They are 
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socio-technical objects. The pun regarding the “saving” of Belgian fries reveals another 
important facet of gene edited organisms: they are also geopolitical objects. In the reports 
we have analysed, Dutch horticulture, Italian grapes, and Swedish potatoes have been put 
forward as relevant issues. Even the call for the “advancement of European science” made in 
the 2019 report by the Comisión Nacional de Bioseguridad is not only an argument about 
knowledge, but also about politics. In a similar way, the report by the Danish Council on 
Ethics interweaves its specific argument for a renewal of the EU legislation regarding GEOs 
with more general references to UN Sustainable Development Goals that might be attained 
by means of new gene editing tools. In other words, the report translates complex and 
planetary problems such as climate change and hunger into the less complex (and easier-to-
imagine) problems of finding the right tools and indicators.  
These kinds of entanglements between the technical, the social and the political are 
particularly interesting to examine and compare. While we have analysed these 
entanglements across national and institutional positions, there is scope for further analysing 
national policies in more detail. This could be done, for instance, by looking more specifically 
at the history and the making of policies in a given country/institution and how different 
kinds of expertise and scientific disciplines are mobilised in this process. If one moves 
beyond the neatly crafted world of policy reports and position statements, the picture gets 
more complex (and would require further analyses).5 This could also entail an analysis of the 
objectification of gene editing: how are gene edited organisms rendered tangible, 
discussable and public via policy processes? How are they tied to national territories, 
identities, histories or products and how, if at all, does this “(re)nationalizing” of gene edited 
organisms matter within and beyond EU member states?  
Given that gene edited organisms raise technical, social, ethical, legal and political issues, 
how are they to be governed? Our paper has shown that there are a number of similarities, 
but also a great number of differences in terms of how their governance is problematized. 
Some reports are the result of a framing that mainly focused on technology, risk and 
regulation, whereas other reports considered ethics, intellectual property, and societal issues 
as well. And while some reports considered gene editing in itself, others chose to situate 
gene editing within larger debates about agriculture, gene drives, medicine, public 
participation, and the responsibility of scientists. Given that the governance of gene editing 
can hardly be confined to national boundaries, expertise and policy about gene editing is 
also very likely to cross national borders. However, this is not necessarily an easy and smooth 
process: the divergences across positions within EU member states make a synthesis and 
common view difficult to achieve. Can diverse European policy options for GEOs co-exist 
and what consequences would this coexistence have? Asked differently: could gene editing 
become a “European object” (Laurent 2019), and if so, how? The ruling of the EU Court of 
                                                   
5 If one takes a look, for example, at Germany’s agricultural policy arena, one can observe a proliferation of 
positions that are far from convergent: the Federal Agency for Nature Conservation “welcomes” the European 
Court of Justice ruling with reference to the precautionary principle, whereas the Federal Office of Consumer 
Protection and Food Safety takes the opposite view; at the level of farmers' associations, the conventionally 
oriented “Deutscher Bauernverband” argues that “CRISPR/CAS-9 cannot be meaningfully regulated with the 
existing genetic engineering law”, whereas an umbrella organization of the German organic sector (BÖLW) 
supports the ruling. 
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Justice is a key site which addresses this question. The ruling not only assesses the technical 
aspects of GEOs, it also defines and constitutes them as a very specific kind of object: an 
object that, in Europe, requires regulatory oversight. Whether one agrees with this ruling or 
not, further debates about the entanglement - and disentanglement - between the law and 
technology are to be expected. We hope that our paper will provide a useful resource to 
broaden debates on the future regulation of gene editing within and beyond Europe.  
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